BidaskClub cut shares of Medpace (NASDAQ:MEDP) from a hold rating to a sell rating in a report issued on Tuesday.

A number of other brokerages have also issued reports on MEDP. Jefferies Group boosted their price target on Medpace from $34.00 to $38.00 and gave the stock a hold rating in a research report on Wednesday, November 1st. William Blair lowered Medpace from an outperform rating to a market perform rating in a research report on Wednesday, November 1st. They noted that the move was a valuation call. Robert W. Baird boosted their price target on Medpace from $32.00 to $35.00 and gave the stock a neutral rating in a research report on Tuesday, October 31st. Zacks Investment Research lowered Medpace from a buy rating to a hold rating in a research report on Tuesday, November 14th. Finally, KeyCorp reiterated a hold rating on shares of Medpace in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. Medpace has a consensus rating of Hold and a consensus price target of $36.60.

Medpace (NASDAQ:MEDP) opened at $33.20 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68. Medpace has a 12-month low of $21.76 and a 12-month high of $39.64. The stock has a market capitalization of $1,238.86, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 1.69 and a beta of -0.96.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.04. Medpace had a return on equity of 10.00% and a net margin of 6.44%. The company had revenue of $98.68 million during the quarter, compared to analyst estimates of $96.84 million. During the same quarter in the previous year, the firm posted $0.40 EPS. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. sell-side analysts expect that Medpace will post 1.5 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of MEDP. Bernzott Capital Advisors raised its stake in shares of Medpace by 141.4% in the 2nd quarter. Bernzott Capital Advisors now owns 593,840 shares of the company’s stock worth $17,221,000 after buying an additional 347,804 shares in the last quarter. Granite Investment Partners LLC bought a new stake in shares of Medpace in the 2nd quarter worth $8,118,000. Redmile Group LLC bought a new stake in shares of Medpace in the 2nd quarter worth $6,526,000. Ameriprise Financial Inc. bought a new stake in shares of Medpace in the 2nd quarter worth $6,402,000. Finally, Vanguard Group Inc. raised its stake in shares of Medpace by 23.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,014,439 shares of the company’s stock worth $29,419,000 after buying an additional 191,597 shares in the last quarter. 16.80% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Medpace (MEDP) Downgraded to “Sell” at BidaskClub” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/06/medpace-medp-downgraded-to-sell-at-bidaskclub.html.

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Stock Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related stocks with our FREE daily email newsletter.